Fibulin-1上调P16、P21和P53促进血管平滑肌细胞衰老的研究

doi:10.3969/j.issn.1003-9198.2026.04.006

Abstract

Abstract: Objective To explore the effect of Fibulin-1 on the senescence of vascular smooth muscle cells (VSMC) and its possible mechanisms. Methods VSMCs of rat cultured in vitro were divided into three groups for the experiment. The control group was DMEM culture medium without D-galactose, the D-galactose group was DMEM culture medium containing D-galactose, and the experimental group was DMEM culture medium with Fibulin-1 recombinant protein and D-galactose. β-galactosidase staining was used to analyze the cell senescence among each group, transmission electron microscopy was used to observe the ultrastructural changes of cells, and Western blot method was used to detect the protein expressions of P16, P21 and P53. Results β-galactosidase staining analysis showed that the number of senescent cells in the D-galactose group and the experimental group was significantly increased compared with the control group, especially in the expermental group(P<0.05). Through the transmission electron microscopy, we found that the nuclei and extranuclear organelles of the cells in the experimental group showed more obvious senescence changes. The expressions of P16, P21 and P53 proteins in the D-galactose group and the experimental group were significantly increased than those in the control group, especially in the experimental group (P<0.05). Conclusions The Fibulin-1 recombinant protein promotes the aging signs of VSMC at both cellular and sub-cellular levels, and its mechanism may be related to Fibulin-1 upregulating the expressions of cell cycle inhibitory proteins P16, P21 and P53.

Key words: Fibulin-1, vascular smooth muscle cells, senescence, P16, P21, P53

CLC Number:

R 329.2

HUANG Rong, HOU Jiwen, JIANG Hua, ZHANG Dan, WANG Zikai. Study on Fibulin-1 upregulating P16, P21, and P53 to promote VSMC senescence[J]. Practical Geriatrics, 2026, 40(4): 357-361.

References

[1] DING Y N, TANG X, CHEN H Z, et al. Epigenetic regulation of vascular aging and age-related vascular diseases[J]. Adv Exp Med Biol, 2018, 1086:55-75.
[2] CHILDS B G, GLUSCEVIC M, BAKER D J, et al. Senescent cells:an emerging target for diseases of ageing[J]. Nat Rev Drug Discov, 2017, 16(10):718-735.
[3] TIAN X L, LI Y. Endothelial cell senescence and age-related vascular diseases[J]. J Genet Genomics, 2014, 41(9):485-495.
[4] PALOMBO C, KOZAKOVA M. Arterial stiffness, atherosclerosis and cardiovascular risk:pathophysiologic mechanisms and emerging clinical indications[J]. Vascul Pharmacol, 2016, 77:1-7.
[5] BASATEMUR G L, JØRGENSEN H F, CLARKE M C H, et al. Vascular smooth muscle cells in atherosclerosis[J]. Nat Rev Cardiol, 2019, 16(12):727-744.
[6] MIANO J M, FISHER E A, MAJESKY M W. Fate and state of vascular smooth muscle cells in atherosclerosis[J]. Circulation, 2021, 143(21):2110-2116.
[7] HANSEN M L, RASMUSSEN L M. Associations between plasma fibulin-1, pulse wave velocity and diabetes in patients with coronary heart disease[J]. J Diabetes Complications, 2015, 29(3):362-366.
[8] ARGRAVES W S, GREENE L M, COOLEY M A, et al. Fibulins:physiological and disease perspectives[J]. EMBO Rep, 2003, 4(12):1127-1131.
[9] 梁小璐, 晏丹, 罗曼蒂, 等. 腓骨蛋白-1在血管平滑肌细胞衰老相关钙化中的作用及机制研究[J]. 中华老年医学杂志, 2022, 41(5):580-585.
[10] WEI W, JI S. Cellular senescence:molecular mechanisms and pathogenicity[J]. J Cell Physiol, 2018, 233(12):9121-9135.
[11] TWAL W O, HAMMAD S M, GUFFY S L, et al. A novel intracellular fibulin-1D variant binds to the cytoplasmic domain of integrin beta 1 subunit[J]. Matrix Biol, 2015, 43:97-108.
[12] ARGRAVES W S, COOLEY M A, HARIKISHNAN K, et al. Fibulin-1 is a matricellular regulator of the RAS/mitogen activated protein kinase (MAPK)-mediated signal transduction pathway[J]. FASEB J, 2009, 23(S1):309.1.
[13] AZMAN K F, ZAKARIA R. D-Galactose-induced accelerated aging model:an overview[J]. Biogerontology, 2019, 20(6):763-782.
[14] JEYAPALAN J C, SEDIVY J M. Cellular senescence and organismal aging[J]. Mech Ageing Dev, 2008, 129(7/8):467-474.

Study on Fibulin-1 upregulating P16, P21, and P53 to promote VSMC senescence

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Metrics

Recommended 10

[1]	LIU Wen, LIU Yuting, JI Muhuo. T cell mitochondrial dysfunction link to postoperative delirium in elderly thoracic surgery patients [J]. Practical Geriatrics, 2026, 40(4): 382-388.
[2]	CHEN Xuguan, XIA Yudong, WANG Yingying, XU Yunfan, WU Jun. Mechanism of macrophage senescence-driven atherosclerosis based on single-cell multi-omics analysis [J]. Practical Geriatrics, 2026, 40(3): 241-246.
[3]	YAO Zitong, DANG Xiaoyu, FAN Haoling, ZHU Xiangyu, HUANG Jingjing, FENG Ganzhu. Research advances in hematologic impairments combined with respiratory viral infections in the elderly [J]. Practical Geriatrics, 2026, 40(2): 206-210.
[4]	LI Hong, LI Shubin, WU Qian, YIN Yaning, SUN Yuxin, Gerileqiqige, LI Weihong, ZHANG Shiqi, WU Zhenli. Research progress on the regulatory mechanism of acetylation in vascular aging [J]. Practical Geriatrics, 2026, 40(1): 72-77.
[5]	YAO Yuan, YANG Yong. Advances in the mechanisms of immunosenescence in elderly patients with non-small cell lung cancer [J]. Practical Geriatrics, 2025, 39(9): 947-951.
[6]	CHEN Jiayu, REN Binhui. Advance of the mechanism of aging-related tumor metastasis [J]. Practical Geriatrics, 2025, 39(8): 851-856.
[7]	CHEN Mengqi, FAN Haoling, ZHANG Yuanyuan, WU Tingyu, ZHANG Dongmei, CHENG Kai. Effects of early time-restricted feeding on metabolic status and senescence-associated secretory phenotype in patients with metabolic syndrome [J]. Practical Geriatrics, 2025, 39(7): 669-673.
[8]	ZHAO Shuqing, ZHAO Ying, ZHANG Yu, LU Xiaohui. A review of cellular senescence in chronic heart failure [J]. Practical Geriatrics, 2025, 39(1): 93-97.
[9]	ZHUO Li, LIU Fu-You, CAI Guang-Yan, WANG Yang, SHI Suo-Zhu. Ｅxpression of p21WAF1/CIP1/SDI1 in aging rat kidneys [J]. Practical Geriatrics, 2010, 24(2): 113-117.